Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Sarcoma 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 10Adenocarcinoma of Lung 7Neoplasms 6Neoplasm Metastasis 5Melanoma 3Glioblastoma 3Carcinoma 3cMET-dysregulated Advanced Solid Tumors 2Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 6 1Neuroblastoma 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Lymphoproliferative Disorders 1Liver Neoplasms 1Laryngeal Diseases 1Kidney Neoplasms 1Hepatic Impairment 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasm Metastasis × capmatinib × Clear all
NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed
603 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT03742349 2025-05-18

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Novartis

Phase 1 Terminated
64 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Novartis

Phase 2 Completed
373 enrolled 34 charts 2 FDA
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03240393 2018-07-26

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Novartis

Phase 2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01072266 2017-11-22

A Dose-escalation Study in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡